Physician profile
Kent Edwin Erickson
NPI 1073516035
$3,140.50
in general payments reported to CMS, 2019-2025
25 companies · $93.55 in 2025
The $93.55 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $589 · 2020: $381 · 2021: $669 · 2022: $596 · 2023: $394 · 2024: $418 · 2025: $93.55.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $815 · Education: $89.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $814.99 |
| Education | $89.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $487.78 | 2019-2024 | Yupelri |
| Pfizer INC. | $368.35 | 2019-2024 | |
| Amgen INC. | $322.07 | 2019-2024 | Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $303.54 | 2019-2024 | Jardiance, Synjardy, Tradjenta |
| Lilly USA, LLC | $287.74 | 2019-2024 | Mounjaro, Jardiance, Emgality |
| Novartis Pharmaceuticals Corporation | $238.45 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $234.98 | 2020-2024 | Airsupra, Breztri, Farxiga |
| Harmony Biosciences LLC | $155.00 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $138.77 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $92.41 | 2020 | |
| Amarin Pharma, INC. | $78.66 | 2021-2022 | |
| Novo Nordisk INC | $57.09 | 2021-2025 | Wegovy |
| Xeris Pharmaceuticals, INC. | $55.55 | 2022-2023 | Gvoke Hypopen |
| Dexcom, INC. | $38.95 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $37.56 | 2021-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $37.21 | 2021 | |
| Abbvie INC. | $35.72 | 2021-2023 | |
| Esperion Therapeutics, INC. | $32.96 | 2021-2024 | Nexletol |
| Abiomed | $27.47 | 2025 | |
| Viatris Specialty LLC | $25.09 | 2025 | Yupelri |
| Sanofi Pasteur INC. | $21.91 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.98 | 2019 | |
| Jazz Pharmaceuticals INC. | $16.56 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $14.78 | 2021 | |
| Sanofi-Aventis U.S. LLC | $13.92 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kent Erickson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.